Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CRNX Stock Alerts

Crinetics Pharmaceuticals (CRNX) Financials

Crinetics Pharmaceuticals logo
$42.16 +1.42 (+3.47%)
As of 01:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Crinetics Pharmaceuticals

Annual Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Consolidated Net Income / (Loss)		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Net Income / (Loss) Continuing Operations		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Total Pre-Tax Income 		-6.02 -9.16 -27 -50 -74 -108 -164 -209 -298 -465
Total Operating Income		 -6.04 -9.13 -29 -54 -75 -108 -168 -223 -339 -517
Total Gross Profit		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04 6.62
Total Revenue		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04 7.70
Operating Revenue		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04 7.70
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.08
Operating Cost of Revenue		 - - - - - - - 0.00 0.00 1.08
Total Operating Expenses		 6.63 11 31 55 75 109 173 227 340 523
Selling, General & Admin Expense		 1.53 1.94 6.66 14 18 25 42 58 100 191
Research & Development Expense		 5.10 9.23 24 42 57 84 130 169 240 332
Total Other Income / (Expense), net		 0.03 -0.03 1.60 3.41 0.99 0.16 3.96 13 41 52
Interest & Investment Income		 0.04 0.03 1.75 3.46 0.99 0.16 3.31 13 41 52
Other Income / (Expense), net		 -0.00 -0.05 -0.15 -0.05 0.00 0.00 0.66 -0.16 -0.52 -0.36
Income Tax Expense		 - - - - - - - 0.00 0.00 0.18
Other Gains / (Losses), net		 - - - - - - - -5.20 -0.47 0.00
Basic Earnings per Share		 ($5.96) ($6.68) ($2.23) ($2.09) ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Weighted Average Basic Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 51.98M 58.07M 80.78M 94.06M
Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) ($2.09) ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Weighted Average Diluted Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 51.98M 58.07M 80.78M 94.06M
Weighted Average Basic & Diluted Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 53.91M 69.60M 93.05M 104.71M

Quarterly Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -51 -57 -61 -67 -74 -77 -83 -97 -116 -130 -123
Consolidated Net Income / (Loss)		 -51 -57 -60 -67 -74 -77 -81 -97 -116 -130 -123
Net Income / (Loss) Continuing Operations		 -51 -57 -60 -67 -74 -77 -81 -97 -116 -130 -123
Total Pre-Tax Income 		-51 -57 -60 -67 -74 -77 -81 -97 -116 -130 -123
Total Operating Income		 -53 -59 -63 -74 -83 -88 -95 -111 -129 -143 -134
Total Gross Profit		 0.99 0.35 - 0.64 0.40 0.00 - 0.36 1.03 0.14 5.09
Total Revenue		 0.99 0.35 - 0.64 0.40 0.00 - 0.36 1.03 0.14 6.16
Operating Revenue		 0.99 0.35 - 0.64 0.40 0.00 - 0.36 1.03 0.14 6.16
Total Cost of Revenue		 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 1.08
Total Operating Expenses		 54 59 63 74 83 88 95 112 130 143 139
Selling, General & Admin Expense		 13 15 17 21 25 26 28 36 50 52 54
Research & Development Expense		 41 44 46 53 58 62 67 76 80 90 85
Total Other Income / (Expense), net		 2.02 1.52 2.56 6.60 8.73 11 14 15 13 12 11
Interest & Investment Income		 2.11 1.57 2.52 6.85 8.74 11 14 15 13 13 11
Other Income / (Expense), net		 -0.09 -0.05 - -0.25 -0.01 -0.04 - -0.20 0.02 -0.05 -0.13
Basic Earnings per Share		 ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30)
Weighted Average Basic Shares Outstanding		 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M
Diluted Earnings per Share		 ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30)
Weighted Average Diluted Shares Outstanding		 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M
Weighted Average Basic & Diluted Shares Outstanding		 54.69M 66.80M 69.60M 78.86M 80.04M 92.74M 93.05M 93.68M 94.18M 94.89M 104.71M

Annual Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -5.71 2.04 31 -4.65 53 108 -167 22 210 -163
Net Cash From Operating Activities		 -5.47 -9.48 -19 -46 -62 -89 -115 -169 -230 -378
Net Cash From Continuing Operating Activities		 -5.47 -9.48 -19 -46 -62 -89 -115 -169 -230 -378
Net Income / (Loss) Continuing Operations		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Consolidated Net Income / (Loss)		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Depreciation Expense		 0.09 0.13 0.47 0.89 0.95 0.92 0.98 1.10 2.79 3.89
Amortization Expense		 - - -0.43 -1.23 -0.23 0.42 0.03 -8.27 -15 -15
Non-Cash Adjustments To Reconcile Net Income		 0.27 0.27 2.32 6.52 11 17 29 47 73 94
Changes in Operating Assets and Liabilities, net		 0.19 -0.72 5.30 -2.13 0.38 1.10 19 5.75 7.41 4.84
Net Cash From Investing Activities		 -0.19 -0.30 -119 42 0.22 -56 -174 -200 -575 174
Net Cash From Continuing Investing Activities		 -0.19 -0.30 -119 42 0.22 -56 -174 -200 -575 174
Purchase of Property, Plant & Equipment		 -0.19 -0.30 -1.06 -0.49 -0.19 -0.44 -1.66 -4.69 -3.84 -5.76
Purchase of Investments		 - - -118 -108 -136 -125 -330 -528 -1,147 -1,004
Sale and/or Maturity of Investments		 - - 0.00 150 136 69 157 337 576 1,184
Other Investing Activities, net		 - - - - - - 0.00 -5.00 0.00 0.00
Net Cash From Financing Activities		 -0.05 12 170 0.07 115 253 122 391 1,015 41
Net Cash From Continuing Financing Activities		 -0.05 12 170 0.07 115 253 122 391 1,015 41
Repurchase of Common Equity		 - - - - - - - -0.54 -15 0.00
Issuance of Common Equity		 - - 106 0.00 114 250 117 370 985 0.00
Other Financing Activities, net		 - 0.07 0.45 0.13 0.29 3.14 4.72 22 45 41

Quarterly Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -1.64 103 -88 341 -94 15 -53 -170 -41 57 -9.76
Net Cash From Operating Activities		 -46 -41 -39 -53 -46 -63 -65 -88 -86 -111 -93
Net Cash From Continuing Operating Activities		 -46 -41 -39 -53 -46 -63 -65 -88 -86 -111 -93
Net Income / (Loss) Continuing Operations		 -51 -57 -60 -67 -74 -77 -81 -97 -116 -130 -123
Consolidated Net Income / (Loss)		 -51 -57 -60 -67 -74 -77 -81 -97 -116 -130 -123
Depreciation Expense		 0.28 0.27 0.26 0.47 0.75 0.77 0.79 0.93 0.96 1.01 0.99
Amortization Expense		 -0.91 -1.25 -3.58 -3.85 -3.41 -3.51 -4.16 -4.38 -4.71 -3.60 -2.73
Non-Cash Adjustments To Reconcile Net Income		 10 12 17 15 20 19 20 21 27 21 25
Changes in Operating Assets and Liabilities, net		 -4.42 4.85 8.30 2.69 11 -2.15 -0.31 -9.54 6.60 1.08 6.69
Net Cash From Investing Activities		 31 -193 -87 0.31 -54 21 -542 -86 38 165 57
Net Cash From Continuing Investing Activities		 31 -193 -87 0.31 -54 21 -542 -86 38 165 57
Purchase of Property, Plant & Equipment		 -0.24 -3.50 -0.94 -1.33 -0.96 -0.53 -1.03 -1.24 -3.20 -0.86 -0.46
Purchase of Investments		 -59 -278 -168 -100 -192 -130 -725 -391 -183 -217 -214
Sale and/or Maturity of Investments		 91 88 87 101 139 151 184 306 224 382 271
Net Cash From Financing Activities		 13 338 38 394 5.50 57 554 4.44 7.06 3.08 26
Net Cash From Continuing Financing Activities		 13 338 38 394 5.50 57 554 4.44 7.06 3.08 26
Other Financing Activities, net		 1.35 8.92 9.17 10 9.81 11 9.54 4.44 7.06 3.08 26

Annual Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 130 183 351 352 635 1,435 1,126
Total Current Assets		 15 123 177 345 345 574 1,375 1,048
Cash & Equivalents		 14 40 93 201 33 55 265 102
Restricted Cash		 - - - - - 0.00 0.50 0.00
Short-Term Investments		 - 78 78 133 302 504 1,090 926
Accounts Receivable		 - - - - - - 0.00 0.59
Inventories, net		 - - - - - - 0.00 2.02
Prepaid Expenses		 0.97 4.95 6.61 11 11 16 21 18
Plant, Property, & Equipment, net		 0.40 3.95 3.18 2.83 3.50 11 12 14
Total Noncurrent Assets		 0.03 3.09 2.77 3.47 3.49 50 47 64
Other Noncurrent Operating Assets		 0.03 3.09 2.77 2.46 3.49 50 47 64
Total Liabilities & Shareholders' Equity		 16 130 183 351 352 635 1,435 1,126
Total Liabilities		 0.92 13 15 19 36 96 110 134
Total Current Liabilities		 0.90 8.34 10 16 28 44 60 85
Accounts Payable		 0.40 5.50 5.59 8.47 15 23 21 42
Accrued Expenses		 0.18 2.12 4.07 6.59 9.08 15 29 36
Current Deferred Revenue		 - - - 0.00 2.24 2.06 2.18 1.24
Other Current Liabilities		 - 0.72 0.84 0.94 1.05 4.17 7.15 6.49
Total Noncurrent Liabilities		 0.02 4.90 4.04 3.08 8.13 52 50 49
Noncurrent Deferred Revenue		 0.02 - - 0.00 6.10 4.75 4.70 3.81
Other Noncurrent Operating Liabilities		 - 4.85 4.01 3.07 2.02 48 45 45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -15 117 169 332 316 539 1,325 992
Total Preferred & Common Equity		 -15 117 169 332 316 539 1,325 992
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -15 117 169 332 316 539 1,325 992
Common Stock		 1.24 211 337 608 759 1,192 2,276 2,408
Retained Earnings		 -16 -94 -168 -275 -439 -654 -952 -1,417
Accumulated Other Comprehensive Income / (Loss)		 - 0.15 0.03 -0.38 -3.93 0.98 0.96 1.87
Other Equity Adjustments		 - - - - - - 0.00 -0.11

Quarterly Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 385 314 293 642 978 936 937 1,361 1,290 1,196
Total Current Assets		 378 305 285 576 917 875 878 1,291 1,217 1,121
Cash & Equivalents		 31 41 40 143 396 302 317 95 54 111
Restricted Cash		 - - - - - - - 0.50 0.50 0.50
Short-Term Investments		 337 255 225 412 505 561 545 1,180 1,143 981
Prepaid Expenses		 9.96 9.28 20 21 16 12 15 16 20 28
Plant, Property, & Equipment, net		 3.56 3.27 3.22 9.76 12 12 12 13 15 14
Total Noncurrent Assets		 2.99 5.34 5.22 56 49 49 48 58 58 60
Other Noncurrent Operating Assets		 2.99 5.34 5.22 51 49 49 48 58 58 60
Total Liabilities & Shareholders' Equity		 385 314 293 642 978 936 937 1,361 1,290 1,196
Total Liabilities		 34 34 39 94 103 105 104 107 118 124
Total Current Liabilities		 25 26 33 40 52 54 54 57 68 74
Accounts Payable		 13 16 21 22 29 24 18 32 38 34
Accrued Expenses		 7.72 6.83 8.60 13 15 20 26 17 22 32
Current Deferred Revenue		 2.32 2.12 2.08 1.66 2.46 2.56 1.69 2.21 1.90 1.64
Other Current Liabilities		 1.02 1.08 1.11 3.99 5.79 7.45 7.41 6.88 6.61 6.44
Total Noncurrent Liabilities		 8.95 7.36 6.53 53 51 50 51 50 50 50
Noncurrent Deferred Revenue		 6.65 5.62 5.07 5.14 4.74 4.32 5.20 4.31 3.99 4.11
Other Noncurrent Operating Liabilities		 2.30 1.74 1.46 48 47 46 46 46 46 46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 351 280 254 548 875 831 833 1,254 1,172 1,072
Total Preferred & Common Equity		 351 280 254 548 875 831 833 1,254 1,172 1,072
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 351 280 254 548 875 831 833 1,254 1,172 1,072
Common Stock		 751 768 792 1,142 1,595 1,626 1,702 2,301 2,335 2,365
Retained Earnings		 -394 -485 -536 -594 -721 -795 -872 -1,049 -1,165 -1,295
Accumulated Other Comprehensive Income / (Loss)		 -5.01 -2.51 -1.71 -0.87 0.15 -0.19 2.04 2.00 1.62 2.19
Other Equity Adjustments		 - - - - - - - - -0.11 -0.11

Annual Metrics And Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 247.20% 18.73% -50.86% -88.10% 659.15% 339.42% -15.28% -74.11% 640.71%
EBITDA Growth		 0.00% -51.97% -218.61% -88.11% -36.90% -43.28% -56.27% -37.14% -54.22% -50.39%
EBIT Growth		 0.00% -51.78% -214.58% -86.68% -39.11% -43.69% -55.27% -33.21% -52.34% -52.38%
NOPAT Growth		 0.00% -51.01% -214.56% -87.50% -39.24% -43.69% -55.88% -32.60% -52.22% -52.50%
Net Income Growth		 0.00% -52.13% -196.11% -85.96% -46.39% -45.83% -52.28% -30.88% -39.10% -55.93%
EPS Growth		 0.00% -12.08% 66.62% 6.28% -15.79% -15.70% -12.50% -17.14% 0.00% -34.15%
Operating Cash Flow Growth		 0.00% -73.35% -105.29% -138.35% -33.73% -42.82% -30.05% -44.36% -35.88% -64.18%
Free Cash Flow Firm Growth		 0.00% 0.00% -185.26% -85.76% -42.08% -44.09% -37.03% -50.70% -47.63% -56.45%
Invested Capital Growth		 0.00% 0.00% -100.00% 0.00% -56.50% -41.41% -552.61% -10.07% -49.43% -20.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1,418.31% -23.40% -15.01% 0.00% 401.37%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -6,361.43% -17,009.34% -9.21% -11.02% -8.84% -10.24% -7.57%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.23% -10.59% -7.35% -10.63% -8.12%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.23% -11.02% -7.28% -10.46% -8.15%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.29% -9.48% -7.57% -7.38% -9.98%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -2.19% -5.00% -1.65% 0.81% -9.76%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -21.92% -19.10% -4.18% -8.53% -11.96% -2.03% -13.09% -8.70%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -1,931.36% -8.26% -15.35% -2.21% -15.63% -3.53%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 41.72% -592.71% -1,146.42% -6.52% -72.07% -0.26% -73.63%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 86.02%
EBITDA Margin		 -1,010.70% -442.40% -1,187.19% -4,545.18% -52,276.06% -9,866.23% -3,508.72% -5,680.04% -33,832.44% -6,869.30%
Operating Margin		 -1,026.15% -446.31% -1,182.45% -4,512.32% -52,783.80% -9,990.91% -3,544.06% -5,547.17% -32,613.47% -6,714.77%
EBIT Margin		 -1,026.32% -448.66% -1,188.76% -4,516.51% -52,783.80% -9,990.91% -3,530.19% -5,551.13% -32,663.43% -6,719.41%
Profit (Net Income) Margin		 -1,021.90% -447.78% -1,116.76% -4,226.49% -51,980.28% -9,985.25% -3,460.38% -5,345.85% -28,720.69% -6,046.22%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 99.80% 100.09% 100.00% 100.00% 100.00% 100.04%
Interest Burden Percent		 99.57% 99.80% 93.94% 93.58% 98.68% 99.85% 98.02% 96.30% 87.93% 89.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -2,629.18% -8,270.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -2,590.17% -8,171.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2,504.41% 7,900.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -124.77% -369.46% -86.09% -51.61% -42.98% -50.57% -50.16% -32.02% -40.17%
Cash Return on Invested Capital (CROIC)		 0.00% -2,829.18% -8,070.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -58.82% -370.09% -82.66% -47.77% -40.30% -47.56% -45.12% -32.79% -40.39%
Return on Assets (ROA)		 0.00% -58.71% -347.67% -77.35% -47.04% -40.28% -46.62% -43.45% -28.83% -36.34%
Return on Common Equity (ROCE)		 0.00% 127.70% 378.12% -86.09% -51.61% -42.98% -50.57% -50.16% -32.02% -40.17%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 60.96% 0.00% -43.04% -43.70% -32.43% -51.82% -39.79% -22.52% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.23 -6.39 -20 -38 -52 -75 -118 -156 -237 -362
NOPAT Margin		 -718.30% -312.42% -827.72% -3,158.63% -36,948.66% -6,993.64% -2,480.84% -3,883.02% -22,829.43% -4,700.34%
Net Nonoperating Expense Percent (NNEP)		 0.00% -39.01% -98.90% -21.52% -14.76% -12.76% -13.87% -13.14% -6.40% -8.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -37.15% -28.90% -17.90% -36.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.98%
SG&A Expenses to Revenue		 260.27% 94.82% 274.26% 1,133.19% 12,694.37% 2,275.05% 894.95% 1,447.65% 9,599.33% 2,486.11%
R&D to Revenue		 865.87% 451.49% 1,008.20% 3,479.13% 40,139.44% 7,815.86% 2,749.10% 4,199.53% 23,114.15% 4,314.68%
Operating Expenses to Revenue		 1,126.15% 546.31% 1,282.45% 4,612.32% 52,728.17% 10,099.81% 3,644.06% 5,647.17% 32,713.47% 6,800.79%
Earnings before Interest and Taxes (EBIT)		 -6.05 -9.18 -29 -54 -75 -108 -167 -223 -339 -517
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.95 -9.05 -29 -54 -74 -106 -166 -228 -352 -529
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 5.19 2.75 4.07 3.11 3.56 2.08 2.53
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 5.19 2.75 4.07 3.11 3.56 2.08 2.53
Price to Revenue (P/Rev)		 173.17 49.88 296.90 509.42 3,271.37 1,251.83 207.88 477.97 2,652.90 326.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 241.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 57.46 296.90 410.18 2,067.99 941.33 137.28 338.66 1,349.17 192.51
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.97 -0.97 -1.01 -1.01 -1.01 -1.03 -1.04 -1.03 -1.03
Leverage Ratio		 0.00 1.06 1.06 1.11 1.10 1.07 1.08 1.15 1.11 1.11
Compound Leverage Factor		 0.00 1.06 1.00 1.04 1.08 1.07 1.06 1.11 0.98 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 202.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -102.34% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 64.35 0.00 26.24 17.65 41.47 14.26 10.37 14.46 8.98
Noncontrolling Interest Sharing Ratio		 0.00% 202.34% 202.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 16.91 0.00 14.79 16.92 21.55 12.45 13.07 23.04 12.32
Quick Ratio		 0.00 15.82 0.00 14.20 16.29 20.86 12.06 12.71 22.69 12.09
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.87 -20 -36 -52 -75 -102 -154 -227 -356
Operating Cash Flow to CapEx		 -2,877.89% -3,118.09% -1,837.49% -9,427.03% -33,347.85% -20,318.35% -6,956.82% -3,547.50% -5,878.51% -6,558.87%
Free Cash Flow to Firm to Interest Expense		 0.00 -859.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -497.09 -1,184.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -514.36 -1,222.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.13 0.31 0.02 0.00 0.00 0.01 0.01 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 5.11 0.00 0.00 0.04 0.36 1.50 0.56 0.09 0.58
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10,725.95
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10,725.95
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.49 0.00 -1.25 -1.96 -2.77 -18 -20 -30 -36
Invested Capital Turnover		 0.00 8.42 9.99 -1.90 -0.09 -0.46 -0.45 -0.21 -0.04 -0.23
Increase / (Decrease) in Invested Capital		 0.00 0.49 -0.49 -1.25 -0.71 -0.81 -15 -1.82 -9.85 -6.04
Enterprise Value (EV)		 0.00 118 721 489 294 1,015 650 1,359 1,402 1,482
Market Capitalization		 102 102 721 608 465 1,349 985 1,918 2,756 2,509
Book Value per Share		 $0.00 ($10.96) $0.00 $4.84 $5.13 $6.99 $5.88 $8.07 $14.29 $10.45
Tangible Book Value per Share		 $0.00 ($10.96) $0.00 $4.84 $5.13 $6.99 $5.88 $8.07 $14.29 $10.45
Total Capital		 0.00 15 0.00 117 169 332 316 539 1,325 992
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -14 0.00 -118 -171 -335 -334 -559 -1,355 -1,028
Capital Expenditures (CapEx)		 0.19 0.30 1.06 0.49 0.19 0.44 1.66 4.69 3.84 5.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.08 0.00 -3.39 -3.88 -4.98 -17 -28 -39 -65
Debt-free Net Working Capital (DFNWC)		 0.00 14 0.00 115 167 329 317 530 1,316 963
Net Working Capital (NWC)		 0.00 14 0.00 115 167 329 317 530 1,316 963
Net Nonoperating Expense (NNE)		 1.79 2.77 7.02 13 21 32 46 59 61 104
Net Nonoperating Obligations (NNO)		 0.00 -14 0.00 -118 -171 -335 -334 -559 -1,355 -1,028
Total Depreciation and Amortization (D&A)		 0.09 0.13 0.04 -0.34 0.72 1.34 1.02 -5.17 -12 -12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 3.72% 0.00% -284.41% -2,730.28% -462.15% -358.12% -706.30% -3,740.62% -839.64%
Debt-free Net Working Capital to Revenue		 0.00% 697.70% 0.00% 9,639.48% 117,607.75% 30,493.97% 6,701.73% 13,212.33% 126,631.76% 12,516.50%
Net Working Capital to Revenue		 0.00% 697.70% 0.00% 9,639.48% 117,607.75% 30,493.97% 6,701.73% 13,212.33% 126,631.76% 12,516.50%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Adjusted Weighted Average Basic Shares Outstanding		 1.01M 1.37M 24.10M 0.00 33.03M 47.78B 51.98M 58.07M 80.78M 94.06M
Adjusted Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Adjusted Weighted Average Diluted Shares Outstanding		 1.01M 1.37M 24.10M 0.00 33.03M 47.78B 51.98M 58.07M 80.78M 94.06M
Adjusted Basic & Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.01M 1.37M 12.14M 0.00 30.45M 38.44M 53.91M 69.60M 93.05M 104.71M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.23 -6.39 -20 -38 -52 -75 -118 -156 -237 -362
Normalized NOPAT Margin		 -718.30% -312.42% -827.72% -3,158.63% -36,948.66% -6,993.64% -2,480.84% -3,883.02% -22,829.43% -4,700.34%
Pre Tax Income Margin		 -1,021.90% -447.78% -1,116.76% -4,226.49% -52,085.92% -9,976.35% -3,460.38% -5,345.85% -28,720.69% -6,043.88%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -549.55 -1,146.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -384.62 -798.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -566.82 -1,184.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -401.89 -836.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 125.06% -24.45% 0.00% -76.11% -59.62% -100.00% 0.00% -43.59% 158.40% 0.00% 0.00%
EBITDA Growth		 -25.99% -38.55% -38.53% -59.47% -59.08% -50.95% -48.71% -49.13% -55.47% -60.33% -37.82%
EBIT Growth		 -23.33% -35.94% -31.76% -53.26% -55.97% -48.80% -51.21% -51.27% -55.92% -62.39% -40.89%
NOPAT Growth		 -23.12% -35.72% -31.76% -53.26% -56.21% -48.87% -51.21% -51.51% -55.96% -62.40% -41.08%
Net Income Growth		 -20.30% -37.05% -33.58% -45.52% -45.27% -33.71% -34.11% -44.59% -56.15% -69.33% -52.39%
EPS Growth		 -16.05% -29.49% -7.23% -9.41% 0.00% 4.95% 3.37% -11.83% -30.85% -43.75% -51.16%
Operating Cash Flow Growth		 -63.48% -7.43% -9.40% -29.81% 0.26% -51.97% -67.92% -67.35% -80.19% -76.24% -38.93%
Free Cash Flow Firm Growth		 -384.79% -254.77% -134.00% -19.38% 26.22% 7.18% -34.34% -102.23% -168.82% -151.18% -54.97%
Invested Capital Growth		 53.39% 31.87% -10.07% -64.82% -209.13% -156.46% -49.43% 20.76% 21.30% 30.54% -20.30%
Revenue Q/Q Growth		 -63.12% -64.98% 0.00% 0.00% -37.66% -100.00% 0.00% 0.00% 185.60% -86.13% 4,208.39%
EBITDA Q/Q Growth		 -11.39% -11.70% -9.96% -16.55% -11.12% -6.00% -8.33% -17.26% -15.46% -9.32% 6.67%
EBIT Q/Q Growth		 -10.65% -11.20% -6.15% -17.35% -12.60% -6.08% -7.87% -17.80% -15.67% -10.49% 6.20%
NOPAT Q/Q Growth		 -10.46% -11.29% -6.24% -17.35% -12.59% -6.06% -7.91% -17.58% -15.89% -10.44% 6.26%
Net Income Q/Q Growth		 -10.84% -12.71% -4.59% -11.37% -10.65% -3.74% -4.90% -20.07% -19.49% -12.50% 5.59%
EPS Q/Q Growth		 -10.59% -7.45% 11.88% -4.49% -1.08% -2.13% 10.42% -20.93% -18.27% -12.20% 5.80%
Operating Cash Flow Q/Q Growth		 -12.32% 9.61% 6.83% -37.23% 13.70% -37.72% -2.95% -36.77% 2.94% -28.97% 16.09%
Free Cash Flow Firm Q/Q Growth		 -41.93% 4.75% 9.98% 1.91% 12.28% -19.84% -30.29% -47.65% -16.61% -11.97% 19.61%
Invested Capital Q/Q Growth		 34.06% -11.17% -72.07% -30.67% -23.67% 7.77% -0.26% 30.71% -22.84% 18.60% -73.63%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 82.54%
EBITDA Margin		 -5,436.94% -17,341.91% 0.00% -12,015.94% -21,416.29% 0.00% 0.00% -31,872.30% -12,885.26% -101,555.24% -2,199.82%
Operating Margin		 -5,363.87% -17,045.38% 0.00% -11,488.91% -20,747.62% 0.00% 0.00% -30,860.11% -12,522.99% -99,710.49% -2,169.55%
EBIT Margin		 -5,373.08% -17,060.69% 0.00% -11,488.91% -20,750.88% 0.00% 0.00% -30,916.34% -12,521.05% -99,744.76% -2,171.58%
Profit (Net Income) Margin		 -5,159.82% -16,606.36% 0.00% -10,457.81% -18,560.15% 0.00% 0.00% -26,807.20% -11,216.00% -90,972.73% -1,993.43%
Tax Burden Percent		 100.00% 100.00% 99.91% 100.38% 100.00% 100.00% 99.69% 100.00% 100.00% 100.00% 100.15%
Interest Burden Percent		 96.03% 97.34% 96.00% 90.68% 89.44% 87.47% 85.33% 86.71% 89.58% 91.21% 91.66%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -57.44% -44.36% -50.16% -40.76% -47.66% -40.26% -32.02% -30.84% -36.94% -44.42% -40.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -72.65% -156.97% 0.00% -35.10% -46.78% 0.00% 0.00% -20.09% -15.67% -143.53% -13.05%
Return on Assets (ROA)		 -69.77% -152.79% 0.00% -31.95% -41.84% 0.00% 0.00% -17.42% -14.03% -130.91% -11.98%
Return on Common Equity (ROCE)		 -57.44% -44.36% -50.16% -40.76% -47.66% -40.26% -32.02% -30.84% -36.94% -44.42% -40.17%
Return on Equity Simple (ROE_SIMPLE)		 -72.36% -36.41% 0.00% -26.91% -31.12% -33.36% 0.00% -26.18% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -37 -41 -44 -51 -58 -61 -66 -78 -90 -100 -94
NOPAT Margin		 -3,754.71% -11,931.76% 0.00% -8,042.23% -14,523.33% 0.00% 0.00% -21,602.08% -8,766.09% -69,797.34% -1,518.69%
Net Nonoperating Expense Percent (NNEP)		 -4.13% -3.49% -3.63% -2.58% -2.86% -2.16% -1.49% -1.73% -2.45% -3.10% -2.46%
Return On Investment Capital (ROIC_SIMPLE)		 - - -8.14% - - - -5.01% -6.22% -7.71% -9.31% -9.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.46%
SG&A Expenses to Revenue		 1,350.51% 4,475.14% 0.00% 3,254.38% 6,225.06% 0.00% 0.00% 9,841.00% 4,834.34% 36,548.95% 871.58%
R&D to Revenue		 4,113.36% 12,670.23% 0.00% 8,334.53% 14,622.56% 0.00% 0.00% 21,119.11% 7,788.65% 63,261.54% 1,380.51%
Operating Expenses to Revenue		 5,463.87% 17,145.38% 0.00% 11,588.91% 20,847.62% 0.00% 0.00% 30,960.11% 12,622.99% 99,810.49% 2,252.09%
Earnings before Interest and Taxes (EBIT)		 -53 -59 -63 -74 -83 -88 -95 -112 -129 -143 -134
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -60 -66 -77 -85 -91 -98 -115 -133 -145 -136
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.82 2.93 3.56 2.88 2.91 3.31 2.08 1.44 1.32 2.09 2.53
Price to Tangible Book Value (P/TBV)		 3.82 2.93 3.56 2.88 2.91 3.31 2.08 1.44 1.32 2.09 2.53
Price to Revenue (P/Rev)		 200.96 339.53 477.97 1,278.36 1,743.38 2,651.34 2,652.90 2,379.08 1,113.81 1,462.74 326.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 146.24 221.08 338.66 821.94 1,120.31 1,821.05 1,349.17 701.95 253.99 750.82 192.51
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.03 -1.04 -1.04 -1.04 -1.03 -1.03 -1.02 -1.03 -1.03 -1.03
Leverage Ratio		 1.12 1.14 1.15 1.12 1.13 1.14 1.11 1.10 1.11 1.12 1.11
Compound Leverage Factor		 1.07 1.11 1.11 1.01 1.01 1.00 0.95 0.95 1.00 1.02 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 12.78 9.67 11.20 14.45 13.40 15.28 15.02 9.85 7.36 10.02 10.10
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.73 14.23 13.07 17.72 16.09 16.38 23.04 22.53 17.80 15.12 12.32
Quick Ratio		 8.11 13.71 12.71 17.40 15.87 16.11 22.69 22.23 17.49 14.73 12.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -49 -47 -42 -41 -36 -43 -56 -83 -97 -109 -88
Operating Cash Flow to CapEx		 -19,297.47% -1,181.11% -4,119.25% -3,968.17% -4,776.65% -11,898.30% -6,285.13% -7,138.98% -2,681.17% -12,829.43% -20,284.06%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.52 0.71 0.56 0.26 0.18 0.10 0.09 0.06 0.10 0.12 0.58
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10,725.95
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10,725.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -10 -12 -20 -26 -32 -30 -30 -21 -25 -21 -36
Invested Capital Turnover		 -0.30 -0.33 -0.21 -0.09 -0.07 -0.05 -0.04 -0.03 -0.05 -0.06 -0.23
Increase / (Decrease) in Invested Capital		 12 5.41 -1.82 -10 -22 -18 -9.85 5.40 6.86 9.07 -6.04
Enterprise Value (EV)		 707 1,044 1,359 1,623 1,552 1,892 1,402 533 354 1,153 1,482
Market Capitalization		 971 1,603 1,918 2,523 2,415 2,755 2,756 1,808 1,550 2,245 2,509
Book Value per Share		 $4.70 $10.02 $8.07 $12.57 $10.53 $10.41 $14.29 $13.48 $12.51 $11.38 $10.45
Tangible Book Value per Share		 $4.70 $10.02 $8.07 $12.57 $10.53 $10.41 $14.29 $13.48 $12.51 $11.38 $10.45
Total Capital		 254 548 539 875 831 833 1,325 1,254 1,172 1,072 992
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -265 -559 -559 -901 -863 -863 -1,355 -1,275 -1,197 -1,093 -1,028
Capital Expenditures (CapEx)		 0.24 3.50 0.94 1.33 0.96 0.53 1.03 1.24 3.20 0.86 0.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -19 -28 -36 -43 -39 -39 -41 -48 -46 -65
Debt-free Net Working Capital (DFNWC)		 252 535 530 865 820 824 1,316 1,234 1,149 1,047 963
Net Working Capital (NWC)		 252 535 530 865 820 824 1,316 1,234 1,149 1,047 963
Net Nonoperating Expense (NNE)		 14 16 16 15 16 15 14 19 25 30 29
Net Nonoperating Obligations (NNO)		 -265 -559 -559 -901 -863 -863 -1,355 -1,275 -1,197 -1,093 -1,028
Total Depreciation and Amortization (D&A)		 -0.63 -0.97 -3.32 -3.37 -2.66 -2.74 -3.38 -3.45 -3.76 -2.59 -1.74
Debt-free, Cash-free Net Working Capital to Revenue		 -255.05% -409.91% -706.30% -1,798.38% -3,072.49% -3,719.25% -3,740.62% -5,378.95% -3,447.70% -2,975.31% -839.64%
Debt-free Net Working Capital to Revenue		 5,217.21% 11,336.23% 13,212.33% 43,843.01% 59,234.58% 79,309.43% 126,631.76% 162,334.74% 82,533.62% 68,216.29% 12,516.50%
Net Working Capital to Revenue		 5,217.21% 11,336.23% 13,212.33% 43,843.01% 59,234.58% 79,309.43% 126,631.76% 162,334.74% 82,533.62% 68,216.29% 12,516.50%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30)
Adjusted Weighted Average Basic Shares Outstanding		 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M
Adjusted Diluted Earnings per Share		 ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30)
Adjusted Weighted Average Diluted Shares Outstanding		 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.69M 66.80M 69.60M 78.86M 80.04M 92.74M 93.05M 93.68M 94.18M 94.89M 104.71M
Normalized Net Operating Profit after Tax (NOPAT)		 -37 -41 -44 -51 -58 -61 -66 -78 -90 -100 -94
Normalized NOPAT Margin		 -3,754.71% -11,931.76% 0.00% -8,042.23% -14,523.33% 0.00% 0.00% -21,602.08% -8,766.09% -69,797.34% -1,518.69%
Pre Tax Income Margin		 -5,159.82% -16,606.36% 0.00% -10,418.59% -18,560.15% 0.00% 0.00% -26,807.20% -11,216.00% -90,972.73% -1,990.50%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Crinetics (CRNX) shows several clear trends across the last four years. The company has substantial liquidity from investments and equity, but operating performance remains negative with ongoing cash burn. Below are the most impactful points, organized with positives first, then neutral, then negatives.

  • Crinetics holds a large liquidity buffer, with Total Current Assets around $1.12B as of Q3 2025, including about $981M in short-term investments and roughly $111M in cash and equivalents.
  • Financing activity has contributed meaningful cash in recent quarters, with Net Cash From Financing Activities around $26.0M in Q4 2025, supporting liquidity amid ongoing losses.
  • In investing activities, Crinetics saw a substantial inflow from the sale/maturity of investments in Q3 2025 (~$382.4M), boosting cash despite operating losses.
  • Equity base remains robust, with Total Common Equity around $1.07B as of Q3 2025, reflecting a sizable common stock position backing the balance sheet.
  • Revenue remains small and volatile: Q4 2025 revenue of about $6.16M follows modest prior quarters, suggesting episodic or milestone-related inflows rather than steady top-line growth.
  • Operating cash flow is consistently negative across quarters, indicating ongoing cash burn to fund operations despite some revenue recognition.
  • Cumulative losses are evident, as retained earnings are heavily negative (approximately -$1.29B by Q3 2025), pointing to sustained funding needs to support ongoing activity.
  • Shares outstanding metrics indicate potential dilution considerations, with weighted-average shares around the 93–105 million range and persistently negative earnings per share.
  • Net income is persistently negative across quarters, e.g., Q4 2025 net income of about -$122.8M and Q3 2025 around -$130.1M, highlighting ongoing profitability challenges.
  • Operating expenses far exceed revenue in 2025, with Total Operating Expenses around $138.8M in Q4 2025 and -133.7M in Total Operating Income, underscoring a continued gap between spending and topline growth.
05/06/26 01:17 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Crinetics Pharmaceuticals' Financials

When does Crinetics Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Crinetics Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Crinetics Pharmaceuticals' net income changed over the last 9 years?

Crinetics Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$465.32 million in 2025, rising from -$6.02 million in 2016. The previous period was -$298.41 million in 2024. See where experts think Crinetics Pharmaceuticals is headed by visiting Crinetics Pharmaceuticals' forecast page.

What is Crinetics Pharmaceuticals' operating income?
Crinetics Pharmaceuticals' total operating income in 2025 was -$516.77 million, based on the following breakdown:
  • Total Gross Profit: $6.62 million
  • Total Operating Expenses: $523.39 million
How has Crinetics Pharmaceuticals' revenue changed over the last 9 years?

Over the last 9 years, Crinetics Pharmaceuticals' total revenue changed from $589 thousand in 2016 to $7.70 million in 2025, a change of 1,206.6%.

How much debt does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals' total liabilities were at $134.17 million at the end of 2025, a 22.2% increase from 2024, and a 14,484.1% increase since 2017.

How much cash does Crinetics Pharmaceuticals have?

In the past 7 years, Crinetics Pharmaceuticals' cash and equivalents has ranged from $14.19 million in 2017 to $264.55 million in 2024, and is currently $101.54 million as of their latest financial filing in 2025.

How has Crinetics Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Crinetics Pharmaceuticals' book value per share changed from 0.00 in 2016 to 10.45 in 2025, a change of 1,045.5%.


Related Companies

Financial statements for NASDAQ:CRNX last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Bigger than SpaceX, Tesla, xAI combined?!
The Wall Street legend who recommended Tesla in 2012 before its 16,724% move reveals... Musk's 2026 Project...
The Oxford Club | Sponsoredtc pixel
Get Ahead of Asia's Market Wave U.S. Solar Growth with PMAX.
Powell Max Limited (NASDAQ: PMAX) operates at the center of Hong Kong's $4.5 trillion capital markets, providi...
Smallcaps Daily | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
When the PC replaced the mainframe, companies that missed the shift went bankrupt. George Gilder - who called ...
Eagle Publishing | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel